Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 2.16 is 970% above its 5-year average of 0.20, around the middle of its 5-year range (-9.75–19.08).
As of the fiscal period ended Tuesday, June 30, 2026. 47.90% above its 12-month average of 1.46.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.16.
DEBT TO EQUITY RATIO
2.16
DEBT TO EQUITY RATIO AVG TTM
1.46
DEBT TO EQUITY RATIO AVG 3Y
-0.68
DEBT TO EQUITY RATIO AVG 5Y
0.20
DEBT TO EQUITY RATIO AVG 10Y
0.43
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+47.90%
CURRENT VS 3Y AVG
+419.32%
CURRENT VS 5Y AVG
+970.43%
CURRENT VS 10Y AVG
+397.13%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
+1860.88%
vs the sector median at left
Akebia Therapeutics, Inc.
Market Cap
$236.39M
Debt to Equity Ratio
2.16
TTM Avg
1.46
3Y Avg
-0.68
5Y Avg
0.20
Market Cap
$236.58M
Debt to Equity Ratio
N/A
TTM Avg
0.09
3Y Avg
0.09
5Y Avg
1.23
Market Cap
$235.68M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$233.10M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$238.45M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$232.88M
Debt to Equity Ratio
0.21
TTM Avg
0.17
3Y Avg
0.14
5Y Avg
0.13
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | $236.39M | 2.16 | 1.46 | -0.68 | 0.20 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $236.58M | N/A | 0.09 | 0.09 | 1.23 |
| Utah Medical Products, Inc. (UTMD)vs › | $235.68M | 0.00 | 0.00 | 0.00 | 0.00 |
| Invivyd, Inc. (IVVD)vs › | $237.34M | 0.05 | 0.01 | 0.01 | 0.01 |
| SIGA Technologies, Inc. (SIGA)vs › | $233.10M | 0.00 | 0.00 | 0.00 | 0.00 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $238.45M | 0.00 | 0.00 | 0.00 | 0.00 |
| High Tide Inc. (HITI)vs › | $238.57M | 1.17 | 1.11 | 0.80 | 1.37 |
| InflaRx N.V. (IFRX)vs › | $233.46M | 0.01 | 0.01 | 0.01 | 0.01 |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $232.88M | 0.21 | 0.17 | 0.14 | 0.13 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.12M | 9.64 | 54.87 | 37.52 | 22.91 |
Debt/Equity
2.16
Current Ratio
1.43
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 2.16 |
| 2026-03-31 | 0.46 |
| 2025-12-31 | 1.59 |
| 2025-09-30 | 1.26 |
| 2025-06-30 | 1.83 |
| 2025-03-31 | 2.20 |
| 2024-12-31 | -3.84 |
| 2024-09-30 | -1.01 |
| 2024-06-30 | -3.10 |
| 2024-03-31 | -1.57 |
| 2023-12-31 | -1.57 |
| 2023-09-30 | -2.89 |
| 2023-06-30 | -4.30 |
| 2023-03-31 | -9.75 |
| 2022-12-31 | 19.08 |
| 2022-09-30 | 11.49 |
| 2022-06-30 | 3.07 |
| 2022-03-31 | 5.18 |
| 2021-12-31 | 2.56 |
| 2021-09-30 | 0.90 |
| 2021-06-30 | 0.71 |
| 2021-03-31 | 0.59 |
| 2020-12-31 | 0.51 |
| 2020-09-30 | 0.33 |
| 2020-06-30 | 0.29 |
| 2020-03-31 | 0.27 |
| 2019-12-31 | 0.27 |
| 2019-09-30 | 0.07 |
| 2019-06-30 | 0.07 |
| 2019-03-31 | 0.06 |
| 2018-12-31 | 0.02 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | 0.00 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
| 2013-12-31 | 0.00 |
| 2013-09-30 | 0.00 |
| 2013-06-30 | 0.00 |
| 2013-03-31 | 0.00 |
| 2012-12-31 | 0.00 |
